• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    The PET-boost trial: isotoxic homogeneous or FDG-directed dose escalation in stage II-III NSCLC

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Cooke, S.
    De Ruysscher, D
    Reymen, B.
    Lambrecht, M.
    Persson, G. F.
    Faivre-Finn, Corinne
    Dieleman, E.
    Lewensohn, R.
    Van Diessen, J.
    Sikorska, K.
    Lalezari, F.
    Sonke, J
    Belderbos, J.
    Show allShow less
    Affiliation
    netherlands Cancer Institute, Department Of Radiation Oncology, Amsterdam,
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    Purpose or Objective The randomized phase II PET-boost trial(NCT01024829) aimed to improve freedom from local failure(FFLF) by boosting either the whole primary tumor(PT) or the high FDG uptake region inside the PT(> 50%SUVmax) in non-small cell lung cancer (NSCLC) patients. Here we report on the primary endpoint FFLF at 1 year, and secondary endpoint overall survival(OS). Material and Methods Eligible patients had stage II-III NSCLC with a primary tumor ≥4 cm, SUVmax ≥5.0 and WHO PS ≤ 2. For each patient, before randomization, a treatment plan (24x2.75Gy) was made for both arms with a simultaneously integrated boost to the whole PT (armA) or to the PT 50%SUVmax area (armB). The boost dose (up to 5.4 Gy per fraction) was maximized by normal tissue constraints while the mean lung dose of the two plans was normalized. In case dose escalation of ≥3 Gy per fraction was not possible, patients were not randomized. Response was assessed with (PET/)CT at 3, 6, 12 and 18 months. All CT-scans were centrally reviewed by a dedicated radiologist. Local failure was defined as 20% growth from nadir (akin to RECIST). The trial was powered(one sided α=0.05;β=0.80) to detect an increase of FFLF at 1 year from 70% (historical rate) to 85%, requiring 82 randomized patients in each arm. Results Between Apr 2010 and Sep 2017, 150 patients were included in 7 institutions. The trial was closed after randomization of 107 patients (initial target 164): 54 to armA and 53 to armB. Patient characteristics are summarized in Table1. Median FU for FFLF was 12.6 months (IQR 5.2-24.6). Median escalated prescribed dose to the PTVwhole tumor (armA) was 3.25 Gy per fraction (IQR 3.13-3.40), and median total dose was 78.0 Gy (IQR 75.0-81.6). Median prescribed dose to the PTV50%SUVmax (armB) was 3.50 Gy per fraction (IQR 3.35-3.90), and median total dose was 84.0 Gy (IQR 80.4-93.6). 72% of patients received concurrent chemo-radiotherapy. Central review showed that the PT was non-measurable in 27% of CT-scans (96/352), mainly due to inflammation, fibrosis and/or atelectasis. If lesions remained stable over time, this was scored as no local failure. In the first year, 22 patients died without known local failure, 16 were lost to CT follow-up and 8 were not-evaluable. The 1-year FFLF rate in evaluable patients was 97% (95% CI 91-100) in armA, and 91% (95% CI 82-100) in armB. The 1- and 3-year OS rates were 77% and 37% in armA, and 62% and 33% in armB, respectively. Conclusion In this randomized phase II trial, dose escalation to the primary tumor as a whole or 50%SUVmax in NSCLC patients led to respectively 97% and 91% FFLF at 1 year in central CT review. Many scans were not evaluable (27%), likely due to the effect of high dose radiation. Predefined FFLF increase from 70% to 85% was achieved in both arms, however the trial did not reach predefined sample size. In locally advanced non-resectable NSCLC a homogeneous boost, sparing central structures as much as possible, should be considered in future research.
    Citation
    Cooke S, De Ruysscher D, Reymen B, Lambrecht M, Persson GF, Faivre-Finn C, et al. OC-0609: The PET-boost trial: isotoxic homogeneous or FDG-directed dose escalation in stage II-III NSCLC. Radiotherapy and Oncology . 2020 Nov;152:S345–6.
    Journal
    Radiotherapy and Oncology
    URI
    http://hdl.handle.net/10541/624331
    Type
    Meetings and Proceedings
    Language
    en
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.